Relapse of acute promyelocytic leukemia (APL) following alltrans retinoic acid (ATRA) therapy has been associated with the acquisition of mutations in the high-affinity ATRA binding site in PML-RARa, but little information is available about the selection dynamics of the mutation-harboring subclones. In this study, 6/18 patients treated with sequential ATRA and chemotherapy on protocol INT0129 relapsed with complete replacement of the nonmutant pretreatment APL cell population by a PML-RARa mutant subclone. Two patients relapsed in proximity of ATRA treatment; however, in four patients there was a 6-48 month hiatus between the last ATRA treatment and relapse. The mutant subclones were not detectable in samples tested X3 months before relapse at X1 in 10 2 (10 À2 ) sensitivity. In one patient, a functionally weak mutation was detected at 10 À4 sensitivity before therapy but only limited pre-relapse enrichment of the mutant subclone was observed on subsequent ATRA therapy. These results indicate that proximate ATRA selection pressure is frequently not the main determinant for the emergence of strongly dominant PML-RARa mutant subclones and suggest that APL subclones harboring PMLRARa mutations are predisposed to the acquisition of secondary genetic/epigenetic alterations that result in a growth/ survival advantage.
Introduction
Hematologic relapse of acute promyelocytic leukemia (APL) following treatment with all-trans retinoic acid (ATRA) alone or in combination with chemotherapy is usually associated with some degree of clinical ATRA resistance. 1, 2 In most cases, an important component of this resistance is reduced sensitivity of the relapse APL cells to ATRA-induced terminal differentiation. [3] [4] [5] Such ATRA-resistant relapse APL cells have been associated with mutations in PML-RARa in an estimated 30% of first-relapse and 65% of multiple-relapse cases. 5, 6 These PMLRARa mutations are localized to the ligand binding domain (LBD) of the RARa-region [5] [6] [7] [8] [9] and variably reduce ATRA binding and gene-regulatory activity. 6, 10 In contrast, pretreatment APL cells are invariably sensitive to saturating, pharmacologicallyachievable ATRA concentrations 5, 11 and have never been reported to contain mutant PML-RARa. 5, 7, 9, 12 At relapse, the APL subclone harboring mutant PML-RARa nearly always completely replaces the originally prevalent nonmutant APL cells, as determined by low-sensitivity DNA sequence analysis. [5] [6] [7] 9 These observations strongly imply that PML-RARa LBD mutations impart a strong competitive advantage to PML-RARa mutant subclones leading to relapse.
Most frequently, relapse with mutant PML-RARa subclone replacement has been reported in patients who are either on or just off of ATRA therapy. 5, [7] [8] [9] This implies that ATRA has a primary role in selecting the ATRA-resistant mutant subclones by extinguishing the residual ATRA-sensitive APL cells via terminal differentiation and/or apoptosis. This in vivo selection mechanism parallels in vitro studies with the APL cell line NB4 in which ATRA-resistant sublines with inactivating mutations of PML-RARa similar to those identified in patients were selected by continuous ATRA exposure. [13] [14] [15] [16] However, in two reported first-relapse cases, a several month delay was noted between the termination of ATRA therapy and relapse with complete PMLRARa mutant subclone replacement. 5, 9 This suggests that continued ATRA selection pressure was not required for the emergence of the replacement mutant subclone but no prerelapse samples were examined in these cases to determine the time at which the PML-RARa mutant subclone displaced nonmutant APL cells. In the current study, we tested all available relapse samples from the first North American intergroup APL clinical trial INT0129 17 for the presence of PML-RARa mutations. In the six mutation-positive cases identified, we tested all prerelapse samples that had been collected in a previous minimal residual disease (MRD) study 18 for PML-RARa mutations by low-sensitivity (p10 À1 ) DNA sequence analysis and, in selected samples, by higher sensitivity (10 À2 -10 À5 ) assays.
Materials and methods

Patients and cell samples
Bone marrow (BM) and peripheral blood (PB) samples with recoverable RNA were utilized from 29 adult APL patients who relapsed on Phase III trial INT0129. Protocol treatment involved two randomizations: (1) to remission induction therapy with either ATRA or chemotherapy (daunorubicin and cytarabine; DC) and (2) after common consolidation chemotherapy with DC, to 1 year of ATRA maintenance therapy or no further treatment (observation; Obs). 17 Hence, this schedule generated four randomization arms: DC/Obs (no ATRA), ATRA/Obs, DC/ATRA and ATRA/ATRA. All patients signed informed consent for correlative laboratory studies according to the Helsinki Declaration.
PML-RARa analyses
Methods for the purification of RNA, synthesis of complementary DNA (cDNA), high-sensitivity allele-specific PCR amplification of PML-RARa, second-round PCR amplification of the LBD region of PML-RARa, and DNA sequence analysis have been previously reported. 5, 19 Also, methods for PML-RARa type determination, 20 monitoring of MRD by real-time quantitative RT-PCR (Q-PCR), 18 measurement of ATRA binding to PMLRARa, 6 and measurement of ATRA transactivation of mutant and wild-type (wt) recombinant PML-RARa constructs in a retinoic acid response-element(RARE)-dependent reporter vector transient transfection assay 6 have been previously reported. For recombinant clone analysis of prerelapse samples from patients with PML-RARa mutations at relapse, second-round PCR products incorporating the mutation sites ( Figure 1a) were cloned into the TOPO TA Cloning Vector (Invitrogen, Carlsbad, CA, USA). 100 clones were analyzed by direct sequencing and/ or by screening for an altered gel electrophoretic pattern after digestion with a restriction endonuclease that differentially cuts mutant and wt sequences.
Mutation-specific primer (MSP) assays were used to test prerelapse samples from cases with relapse mutations affecting RARa codon 394. Second-round, allele-specific PCR products (i.e., segments amplified from primer pair P5 Â P2, Figure 1a ) were used as template in MSP assays after analysis of P5 Â P2 PCR products by Q-PCR to ensure that quantitative amounts of template were used in all comparative studies. The primers used for this Q-PCR determination (not shown in Figure 1a) were: forward primer, 5 0 -GAAGCGGAGGCCCAGC-3 0 ; reverse primer, 5 0 -GCTTCGCAGGTCAGTAATCTTCA-3 0 . The minor groove-binding probe sequence labeled at the 5 0 -end with the fluorescent reporter dye FAM was: 5 0 -CCCCCACATGTTCCC CAAGATGCTA-3 0 (Applied Biosystems, Inc., ABI, Foster City, CA). For Case 6, which contained a 12 nucleotide deletion, the reverse MSP (P8) overlapped the deleted wt sequence by three nucleotides (5 0 -CCGGGATCTCCATCTTCATCT-3 0 ), producing a two nucleotide mismatch (TCT vs GCG). Used with a forward primer P6 (5 0 -CGCCATCTGCCTCATCT-3 0 ), this amplified a 210 nucleotide PCR product in a reaction containing AmpliTaq Goldt polymerase (ABI). For Cases 2 and 5 with a C-T mutation, the template was first digested overnight with BsrB1 restriction endonuclease (New England BioLabs, Beverly, MA, USA), which selectively cuts wt sequence, followed by MSP amplification using with the proof-editing enzyme pfuUltra High-Fidelityt DNA Polymerase (Stratagene, La Jolla, CA, USA). The reverse MSP (P9) substituted the mutant base in the terminal 3 0 position, that is, A vs G (5 0 -CCATCTTCAGCGTGAT CACCCA-3 0 ) and, used with forward primer P7 (5 0 -CAGCGC CATCTGCCTCATCT-3 0 ), generated a 215 nucleotide product. This procedure was not completely effective in proof-editing the
RARα-region of PML-RARα Mutation Sites: terminal mutant A nucleotide from the primer even after extensive restriction endonuclease digestion and purification (Qiaquick PCR Purification kit, Qiagen, Valencia, CA, USA) of wt template, and the resultant low-level background varied somewhat between experiments. However, intraexperiment variation of sample replicates was minimal (o10% from the mean), and, thus, triplicate test and control (wt) samples from the same experiment were assessed for differences in the ratio of mutant to wt peak areas in sequencing chromatograms (Student's t-test).
Results
Identification of PML-RARa mutations
No mutations were detected by standard DNA sequence analysis in the RARa-region of PML-RARa before treatment in all 29 patients or in 11 relapse patients randomized to receive no ATRA (DC/Obs). Conversely, 6/18 (33.3%) ATRA-treated patients were found to harbor PML-RARa mutations. There was no apparent difference in the distribution of mutations by ATRA randomization arm (ATRA/Obs, 3/9; DC/ATRA, 2/6; ATRA/ ATRA, 1/3). Two of the six mutant cases relapsed in proximity to ATRA therapy: Case 3 while on ATRA therapy and Case 2, 49 days after finishing ATRA maintenance therapy (Table 1) . Three mutant cases received ATRA only during remission induction treatment (Cases 1, 4, 6), and these cases, as well as Case 5, relapsed a relatively long time after last ATRA exposure (174-1437 days; Table 1 ).
Characterization of PML-RARa mutations in the RARaregion LBD Figure 1 illustrates the sequencing chromatograms of three relapse patients (Cases 4-6) and depicts the location of all six mutations, including three previously reported patients (Cases 1-3). 5 In all cases, only mutant sequence was apparent in chromatograms after both sense and antisense analysis, indicating replacement of wt PML-RARa, which was exclusively seen before protocol treatment. Table 1 indicates the resultant amino acid changes and semiquantitatively summarizes the effect of the mutations on the ATRA binding properties and ability to transactivate a RARE-driven reporter gene. Three mutations affected the common amino-acid Arg394, two missense mutations (Cases 2 and 5) and a 12 nucleotide deletion that removed amino acids from Arg394 to Leu398, substituting a Met at position 394, maintaining the open reading frame (Case 6). The latter is the first reported deletion mutation in naturally occurring APL. The two Arg394 missense mutations produced modest functional defects, whereas these effects were profound for the deletion mutation and for two other mutations from patients who received ATRA only during induction therapy (Cases 1 and 4; Table 1 ).
Monitoring of prerelapse samples for PML-RARa and PML-RARa mutations
Prerelapse samples from five cases with Long(L)-form or Short(S)-form PML-RARa were monitored for MRD by Q-PCR (Table 2 and Figure 2 ). Case 3 with the Variable(V)-form of PMLRARa was monitored by standard RT-PCR, which was positive for MRD except at CR (not shown). Although MRD was not detectable by Q-PCR in some instances, it was nearly always possible to amplify a low level of residual PML-RARa mRNA for mutation analysis by high-sensitivity manual RT-PCR. No mutations were detected in sequencing chromatograms from any prerelapse sample.
As the detection sensitivity for a minor subpopulation of mutant transcripts in sequencing chromatograms is limited (p10 À1 ), we examined 100 recombinant clones of PCR product from selected samples that preceded relapse by 3 months to 4 years. No recombinant clones positive for mutations were found in samples obtained after the last ATRA dose in Cases 1, 4, 5, and 6 (Table 2) or before ATRA maintenance therapy in Case 3. Conversely, analysis of 100 recombinant clones from the Case 5 relapse sample did not detect any wt clones.
High-sensitivity testing for PML-RARaAA394 mutant prerelapse subclones
All prerelapse specimens from the three cases with Arg394 mutations were tested using higher sensitivity MSP assays. Anticipating that Case 6 with the deletion mutation would provide the highest mutant-to-wt signal, we first developed a quantitative Taq polymerase assay for this mutation (see Materials and methods). In a dilution experiment of mutant into wt template, a gel electrophoretic band of appropriate size was demonstrated at a 10 À5 dilution after 30 PCR cycles without any visible wt signal (Figure 3 ). After 35 PCR cycles, a much stronger mutant signal was visualized but a light, slightly higher band was observed on wt template (wt sequence confirmed). Using this assay, template from the pretreatment and CR samples generated a weak, wt-length gel band after 38 PCR cycles (sequence-confirmed to represent breakthrough wt synthesis). Together, these data indicate that no deletion mutant subclone was detectable in Case 6 at 10 À5 sensitivity either before treatment or at CR after the last dose of ATRA (Table 2) .
To assess the C-T substitution in Cases 2 and 5, the MSP assay was modified to include restriction endonuclease digestion of wt template, use of a proof-editing DNA polymerase, and read-out of the results by sequence analysis (see Materials and methods). A technical shortcoming of this assay was persistent insertion of a low-level mutant base on wt template, which could not be eliminated by substitution of all possible base combinations in the second and third positions from the 3 0 -end of the MSP and by experimental variation of PCR conditions. Nevertheless, in serial dilution experiments, 10 À4 detection sensitivity above the low-level background on wt template was reproducibly achieved with a stoichiometric increase in mutant signal with a decreasing level of mutant dilution (Figure 4a ). By using this assay, the pretreatment and all prerelapse samples from Case 5 were consistently negative (Table 2) . However, a fraction of Case 2 assays were positive, including samples obtained before treatment, after 15 days and 65 days (CR) of induction therapy and during ATRA maintenance treatment (Figure 4b ). The CR sample showed a low-level second base substitution (C-G; five independent assays derived from a common cDNA; no further RNA available), which could represent a second mutation or a polymerase editing error. Samples from the midinduction period (34 and 45 days) and immediately postconsolidation chemotherapy (PCC) were consistently negative. Notably, there was only a Figure 3 Gel electrophoretic analysis of PCR products generated in serial dilutions of mutant template from Case 6 in wt template from NB4 cells after 30 or 35 PCR cycles, as described in Materials and methods. M, fX174 DNA marker.
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Discussion
A primary observation of this study was that subclones with mutant PML-RARa replaced the previously prevalent wt APL cell population at relapse whether or not the patient had been recently treated with ATRA. In two patients who had received ongoing or proximate ATRA treatment, this seemed consistent with the classical selection dynamic for drug-resistant subclones harboring mutations affecting the activity of a specific targeting agent. For example, this has been associated with the emergence of subclones resistant to imatinib, which targets the tyrosine kinase activity of the BCR-ABL fusion gene, in many cases of chronic myeloid leukemia (CML). [21] [22] [23] However, complete mutant subclone replacement after a X6 month hiatus since the last administration of ATRA, as observed in four of our cases and as reported in one previous case, 9 suggests the possibility of a different selection dynamic.
Several further observations and considerations from our study are informative about the dynamics involved in the emergence of the mutant subclones. First, PML-RARa mutant subclones were not observed in 11 patients after relapse from treatment with chemotherapy alone. Second, in one case (Case 2), a low-level PML-RARa mutation was detected before ATRA therapy. Notably, the pretreatment subclone harboring this mutation was initially enriched during ATRA induction therapy Sample checkpoints at which the T-C ratio significantly differed from that of the wt control are indicated by an asterisk (Po0.05).
but this was transient, and, even through 8 months of subsequent ATRA maintenance therapy, the increase in the mutant subclone versus the predominant wt APL cells was quite limited (Figure 4b ). Third, in the four 'hiatus cases', no mutant subclone was detectable in prerelapse samples after the last dose of ATRA at 10 À2 -10 À5 sensitivity (Table 2) . Together, these three observations indicate that some level of initial ATRA selection was required for PML-RARa mutant subclone replacement to subsequently occur in the absence of proximate ATRA treatment, but they further indicate that this initial selection did not empower the mutant subclone with a strong competitive advantage over the predominant APL cells containing wt PMLRARa. These observations also exclude the possibility that initial ATRA treatment might have selected a PML-RARa mutant subclone as a high fraction relative to nonmutant APL cells that was sustained during prerelapse CR until the time of relapse. Thus, these considerations imply that some secondary event was required to empower the mutant PML-RARa subclone to gain sufficient competitive advantage to emerge and displace wt APL cells at relapse. Consistent with the involvement of a secondary, kinetically transforming event, three of our cases (Cases 1, 2, and 5) relapsed with mutant subclone replacement from very low or absent MRD and PML-RARa mutation levels within 3-7 months. Others have also postulated the occurrence of some kinetic transforming event to explain how clinical relapse of APL can suddenly occur from very low or undetectable MRD levels in 3-6 months. 24, 25 Studies with more frequent sampling intervals are required to definitively resolve these kinetic issues. Interestingly, a recent report in CML analogously found that continued imatinib therapy in CML did not necessarily lead to the emergence of selectable BCR-ABL mutant subclones and postulated that additional factors are necessary for the development of a fully drug-resistant and competitive phenotype. 26 If the PML-RARa mutations per se were not the primary factor resulting in relapse, as supported by the above arguments, why were they consistently found in replacement mutant subclones at the time of clinical relapse? As it seems highly improbable that this could have occurred by mere coincidence, we suggest that two aberrant, alternative activities associated with PMLRARa, which are not ATRA-dependent, may be involved. First, PML-RARa has been associated with the disruption of cellular response pathways involved in the repair of DNA damage and the maintenance of genomic stability, which might result in an increased mutation rate. 27, 28 Second, PML-RARa has been reported to recruit DNA methyltransferases and to increase methylation of the promoter region of the RARb2 gene, a suppressor gene containing a RARE. 29 Although both of these mechanisms are primarily effected by the PML-region of PMLRARa, they are influenced by the association of corepressor proteins with the LBD of the RARa-region of PML-RARa, which is increased in parallel with the level of functional defect produced by LBD mutations. 10 In our study, this could be related to the late emergence of APL subclones harboring strong inactivating mutations of PML-RARa in patients who received only limited ATRA during induction therapy (Case 1, 4 and 6; Tables 1 and 2 ). We are further investigating whether these two mechanisms could account for the acquisition of secondary growth-and survival-enhancing aberrations specifically in PMLRARa mutant subclones.
We acknowledge that our interpretations are based on results from case numbers too small for confident general conclusions. However, confirmation and extension of these results in a larger patient cohort may be difficult to achieve, as advances in the treatment of APL have reduced the relapse rate to as low as 10%. 30 Also, the recent incorporation of ATRA into all phases of treatment will further limit relapse sample availability without proximate ATRA treatment, and salvage therapy is more frequently being initiated at the time of molecular relapse rather than clinical relapse, 31 which proscribes facile, low-sensitivity screening for PML-RARa mutations. Nevertheless, we suggest that several questions merit exploration within the evolving APL treatment context. Is the improved clinical outcome observed with concurrently administered ATRA and chemotherapy compared to outcome with these agents administered sequentially, 32 as in the current study, associated with a decreased incidence of PML-RARa mutations at relapse? Do different agents that are not crossresistant to ATRA differentially affect this incidence? Following salvage therapy based on molecular relapse, do patients who subsequently experience hematological relapse have an increased incidence of PML-RARa mutations? Do patients who experience late relapse, that is, two or more years after finishing therapy, have an increased frequency of PML-RARa mutations? Can second-line salvage therapy effectively eliminate mutant subclones? Is the overall survival of relapse patients with predominant PML-RARa mutant subclones different from relapse patients lacking mutant subclones? The answers to these questions will determine whether or not adjustments in molecular monitoring procedures and in treatment applications should be considered to detect and eliminate APL clones harboring PML-RARa mutations in patients with significant levels of MRD.
More generally, this study may provide some insight into the relationship of molecular-targeted drug-resistance and neoplastic subclone progression. If our hypothesis is correct that PMLRARa mutations are not neutral with respect to the acquisition of secondary mutations that provide a competitive subclone advantage, this suggests a different dynamic for predicting the behavior of mutant APL subclones than posited in recent stochastic models based on analyses of BCR-ABL mutations in imatinib-treated CML. 33, 34 Additionally, the prototypic ATRA/ PML-RARa targeted therapy model may be relevant to the nascent therapeutic approach of targeting small molecule regulators to transcription factors in a variety of neoplastic diseases. 35 An inference of our findings is that the development of tumor cell resistance to such agents might not be due just to structural changes that affect interaction with the target molecule but might also involve consequential alterations in other properties of these multifunctional proteins.
